Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Cascone, Tina; Kar, Gozde; Spicer, Jonathan D.; García-Campelo, Rosario; Weder, Walter; Daniel, Davey B.; Spigel, David R.; Hussein, Maen; Mazieres, Julien; Oliveira, Julio; Yau, Edwin H.; Spira, Alexander I.; Anagnostou, Valsamo; Mager, Raymond; Hamid, Oday; Cheng, Lin-Yang; Zheng, Ying; Blando, Jorge; Tan, Tze Heng; Surace, Michael; Rodriguez-Canales, Jaime; Gopalakrishnan, Vancheswaran; Sellman, Bret R.; Grenga, Italia; Soo-Hoo, Yee; Kumar, Rakesh; McGrath, Lara; Forde, Patrick M.

doi:10.1158/2159-8290.24473992.v1

cd-23-0436_supplementary_data_-_supplementary_table_7_suppsd1.pdf (1.89 MB)

Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

journal contribution

posted on 2023-11-01, 08:00 authored by Tina Cascone, Gozde Kar, Jonathan D. Spicer, Rosario García-Campelo, Walter Weder, Davey B. Daniel, David R. Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin H. Yau, Alexander I. Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R. Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M. Forde

Supplementary Table 7. Tumor RNA sequencing. (File too large to be included in main supplementary file).

Funding

N/A

History

ARTICLE ABSTRACT

Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for patients with resectable NSCLC, using major pathologic response (MPR) rate as the primary endpoint. Eighty-three patients received a single cycle of treatment: 26 received durvalumab (anti–PD-L1) monotherapy, 21 received durvalumab plus oleclumab (anti-CD73), 20 received durvalumab plus monalizumab (anti-NKG2A), and 16 received durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide). MPR rates were higher for patients in the combination arms versus durvalumab alone. Safety profiles for the combinations were similar to those of durvalumab alone. Multiplatform immune profiling suggested that improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune cell activation. A neoadjuvant platform trial can rapidly generate clinical and translational data using candidate surrogate endpoints like MPR. In NeoCOAST, patients with resectable NSCLC had improved MPR rates after durvalumab plus oleclumab or monalizumab versus durvalumab alone and tumoral transcriptomic signatures indicative of augmented immune cell activation and function.See related commentary by Cooper and Yu, p. 2306.This article is featured in Selected Articles from This Issue, p. 2293